[go: up one dir, main page]

GT200900096A - Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada - Google Patents

Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Info

Publication number
GT200900096A
GT200900096A GT200900096A GT200900096A GT200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A
Authority
GT
Guatemala
Prior art keywords
dosage forms
chlorhydrate
palonosetron
improved stability
biodisponibility
Prior art date
Application number
GT200900096A
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Ricardo Braglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900096A publication Critical patent/GT200900096A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A FORMAS DE DOSIFICACIÓN ORALES SÓLIDAS DEL CLORHIDRATO DE PALONOSETRON, LOS MÉTODOS PARA USAR LAS FORMAS DE DOSIFICACIÓN PARA TRATAR EL VÓMITO, Y LOS MÉTODOS PARA HACER LAS FORMAS DE DOSIFICACIÓN. LAS FORMAS DE DOSIFICACIÓN HAN MEJORADO LA ESTABILIDAD Y BIODISPONIBILIDAD, Y ESTÁN PREFERIBLEMENTE BAJO LA FORMA DE CÁPSULAS RELLENAS DE LÍQUIDO.
GT200900096A 2006-10-24 2009-04-23 Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada GT200900096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
GT200900096A true GT200900096A (es) 2011-08-29

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900096A GT200900096A (es) 2006-10-24 2009-04-23 Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Country Status (35)

Country Link
US (2) US20080152704A1 (es)
EP (1) EP1940366B9 (es)
JP (1) JP5144527B2 (es)
KR (1) KR101441459B1 (es)
CN (1) CN101573106B (es)
AR (1) AR063362A1 (es)
AT (1) ATE427742T1 (es)
AU (1) AU2007308378B2 (es)
BR (1) BRPI0718497B1 (es)
CA (1) CA2666512C (es)
CL (1) CL2007003055A1 (es)
CO (1) CO6160289A2 (es)
CR (1) CR10728A (es)
CY (1) CY1109914T1 (es)
DE (1) DE602007000856D1 (es)
DK (1) DK1940366T3 (es)
EA (1) EA016455B1 (es)
ES (1) ES2325339T3 (es)
GT (1) GT200900096A (es)
HN (1) HN2009000785A (es)
HR (1) HRP20090341T1 (es)
IL (1) IL198225A (es)
ME (1) ME01949B (es)
MX (1) MX2009004461A (es)
NO (1) NO342353B1 (es)
NZ (1) NZ576237A (es)
PL (1) PL1940366T3 (es)
PT (1) PT1940366E (es)
RS (1) RS50842B (es)
SI (1) SI1940366T1 (es)
SV (1) SV2009003238A (es)
TW (1) TWI367212B (es)
UA (1) UA97653C2 (es)
WO (1) WO2008049552A1 (es)
ZA (1) ZA200902773B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
CN103211779B (zh) * 2006-01-27 2016-03-16 阿代尔制药股份有限公司 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2361090B1 (en) 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2744497B1 (en) 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
WO2014147096A1 (en) * 2013-03-19 2014-09-25 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015099381A1 (ko) * 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
WO2024126408A1 (en) 2022-12-12 2024-06-20 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633612A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3650772T2 (de) * 1985-04-27 2003-04-03 F. Hoffmann-La Roche Ag, Basel Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
PL166272B1 (pl) * 1989-11-28 1995-04-28 Syntex Inc Sposób wytwarzania nowych addycyjnych soli z kwasami zwiazków trójpierscieniowych PL PL PL PL
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
AU2003302072A1 (en) 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
WO2008049552A1 (en) 2008-05-02
EP1940366B1 (en) 2009-04-08
BRPI0718497B1 (pt) 2024-02-06
PL1940366T3 (pl) 2009-09-30
ME01949B (me) 2010-08-31
EP1940366A1 (en) 2008-07-09
CR10728A (es) 2009-07-23
SV2009003238A (es) 2009-11-09
EA016455B1 (ru) 2012-05-30
ZA200902773B (en) 2010-03-31
SI1940366T1 (sl) 2009-08-31
NO342353B1 (no) 2018-05-07
KR20090073234A (ko) 2009-07-02
TW200827355A (en) 2008-07-01
CY1109914T1 (el) 2014-09-10
IL198225A0 (en) 2009-12-24
DE602007000856D1 (de) 2009-05-20
EA200970396A1 (ru) 2009-10-30
ATE427742T1 (de) 2009-04-15
PT1940366E (pt) 2009-06-17
BRPI0718497A2 (pt) 2014-07-08
IL198225A (en) 2013-03-24
KR101441459B1 (ko) 2014-09-18
MX2009004461A (es) 2009-09-16
ES2325339T3 (es) 2009-09-01
JP2009507933A (ja) 2009-02-26
DK1940366T3 (da) 2009-06-29
AU2007308378A1 (en) 2008-05-02
HN2009000785A (es) 2011-10-14
US20080152704A1 (en) 2008-06-26
CA2666512A1 (en) 2008-05-02
HRP20090341T1 (hr) 2009-07-31
CN101573106A (zh) 2009-11-04
CA2666512C (en) 2014-05-27
US20170035748A1 (en) 2017-02-09
RS50842B (sr) 2010-08-31
CN101573106B (zh) 2013-07-24
NO20091945L (no) 2009-05-25
JP5144527B2 (ja) 2013-02-13
AU2007308378B2 (en) 2013-02-21
AR063362A1 (es) 2009-01-21
CL2007003055A1 (es) 2008-03-24
TWI367212B (en) 2012-07-01
NZ576237A (en) 2011-12-22
UA97653C2 (ru) 2012-03-12
EP1940366B9 (en) 2009-12-02
HK1117769A1 (en) 2009-01-23
CO6160289A2 (es) 2010-05-20

Similar Documents

Publication Publication Date Title
GT200900096A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EP3621621C0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MELOXICAM
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
UY33017A (es) Tratamiento para trastornos gastrointestinales
DK2099406T3 (da) Opbevarings- og udleveringsindretninger til administration af oralt transmucosale doseringsformer
CR11709A (es) Preparacion solida de desintegracion oral
BRPI1012831A2 (pt) forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2.
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma
BRPI1007484A2 (pt) composição farmacêutica para administração oral
HUE057788T2 (hu) Eslikarbazepin szilárd orális dózisformái
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
SMT202300074T1 (it) Composizione farmaceutica stabile per somministrazione orale
UY31662A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de elaboracion.
CO7111279A2 (es) Composiciones farmacéuticas orales estables de liberación inmediata que contienen prasugrel
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2337565A4 (en) STABLE SOLID ORAL CO DOSAGE FORMULATIONS
AR084435A1 (es) Combinacion y composicion para el tratamiento de obesidad
DOP2009000091A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
BRPI0919475A2 (pt) composição farmacêutica para administração oral
MX2015011152A (es) Composicion farmaceutica de omeprazol-bicarbonato de sodio para integrar una capsula, para el tratamiento de alopatias relacionadas con la acidez gastrica.